Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating expenses:        
Research and development $ 2,180 $ 1,617 $ 5,190 $ 6,098
General and administrative 1,139 1,044 3,241 2,725
Operating loss (3,319) (2,661) (8,431) (8,823)
Other (income) expense:        
Governmental assistance - research incentives (25) (263) (205) (663)
Other (income) expense, net (103) 38 (154) (20)
Total other income (128) (225) (359) (683)
Loss before income tax expense (3,191) (2,436) (8,072) (8,140)
Income tax expense 2 12 20 29
Net loss (3,193) (2,448) (8,092) (8,169)
Other comprehensive income        
Unrealized gain (loss) on marketable securities (19) (5) 8 6
Net loss and comprehensive loss $ (3,212) $ (2,453) $ (8,084) $ (8,163)
Basic and diluted net loss per share (in dollars per share) $ (0.19) $ (0.20) $ (0.55) $ (0.68)
Weighted average shares outstanding – basic and diluted (in shares) 16,689,074 12,006,874 14,652,749 11,981,233